Open house pharmaceutical discount agreements Bimatoprost, ATC S01EE03
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bimatoprost, ATC S01EE03
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or minimum volume is provided; actual revenue may be low.
Requires submission in paper with two originals or electronic with qualified electronic signature; strict monthly deadl...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2028
- Supply of Bimatoprost (ATC S01EE03) pharmaceutical products
- Non-exclusive discount agreements with AOK Bayern
Show full summary
Open-house model for non-exclusive discount agreements for Bimatoprost (ATC S01EE03) with AOK Bayern. Any eligible pharmaceutical company can join at any time until 03.06.2028. No selection process; contracts are offered to all interested parties meeting eligibility criteria. Contract duration: 01.08.2026 to 31.07.2028. No estimated value provided.
Risks
No estimated value or minimum volume is provided; actual revenue may be low.
Requires submission in paper with two originals or electronic with qualified electronic signature; strict monthly deadl...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical companies may apply
Certifications
- Documents must be in German or accompanied by certified German translation
Administrative
- Submission of signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house pharmaceutical discount agreements Bimatoprost, ATC S01EE03
Non-exclusive discount agreements for Bimatoprost (ATC S01EE03) under the open-house model. Contracts can be concluded at any time until 03.06.2028, with earliest start 01.08.2026. All contracts end 31.07.2028. Terms are identical and non-negotiable.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Bimatoprost, ATC S01EE03
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 406804-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or minimum volume is provided; actual revenue may be low.
Requires submission in paper with two originals or electronic with qualified electronic signature; strict monthly deadl...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications